Nonclinical and Clinical Experiences with CPP-Based Self-Assembling Peptide Systems in Topical Drug Development

Methods in Molecular Biology

Volumn 683, Issue , 2011, Pages 553-572

  Waugh, Jacob M ^a   Lee, Jane ^a   Dake, Michael D ^b   Browne, Dan ^a  

^a Revance Therapeutics Inc   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Botulinum toxin; Hyperhidrosis; Ionic; Lateral canthal lines; TAT

Indexed keywords

CELL PENETRATING PEPTIDE; DRUG CARRIER;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG SCREENING; HUMAN; INTRADERMAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; REVIEW;

ADMINISTRATION, CUTANEOUS; AMINO ACID SEQUENCE; ANIMALS; CELL-PENETRATING PEPTIDES; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR SEQUENCE DATA;

MLCS; MLOWN;

EID: 79952197781     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-919-2_39     Document Type: Chapter

References (23)

1. Scott, A.B. (1981) Botulinum toxin injection of eye muscles to correct strabismus Trans Am Ophthalmol Soc 79, 734–770.
2. Hallett, M. (1999) One man’s poison-clinical applications of botulinum toxin N Engl J Med 341, 118–120.
3. Spencer, J.M. (2002) Botulinum Toxin B. The new option in cosmetic injection J Drugs Dermatol 1, 17–22.
4. Carruthers, A. and Carruthers, J. (2005) Botulinum toxin type A J Am Acad Dermatol 53, 284–290.
5. Carruthers, J. and Carruthers, A. (2007) The evolution of botulinum toxin type A for cosmetic applications J Cosmet Laser Ther 9, 186–192.
6. Carruthers, J. and Carruthers, A. (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin J Dermatol Surg Oncol 18,17–21.
7. Carruthers, J., Fagien, S., Matarasso, S.L., and BOTOX Consensus Group. (2004) Consensus recommendations on the use of botulinum toxin type A in facial aesthetics Plast Reconstr Surg 114:1S–22S.
8. The American Society for Aesthetic Plastic Surgery, Cosmetic Surgery National Data Bank. 2006 statistics. www.surgery.org/ download/2006stats.pdf. Accessed 30 March 2007.
9. Bushara, K.O., Park, D.M., Jones, J.C., and Schutta, H.S. (1996) Botulinum toxin-a possible new treatment for axillary hyperhidrosis Clin Exp Dermatol 21, 276–278.
10. Schnider, P., Binder, M., Berger, T., and Auff, E. (1996) Botulinum A toxin injection in focal hyperhidrosis Br J Dermatol 134, 1160–1161.
11. Naumann, M., Hofmann, U., Bergmann, I., Hamm, H., Tiyka, K.V., and Reiners, K. (1998) Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin Arch Dermatol 134, 301–304.
12. Heckmann, M., Ceballos-Baumann, A.O., and Plewig, G. (2001) Botulinum toxin A for axillary hyperhidrosis (excessive sweating) N Engl J Med 344, 488–493.
13. Naumann, M. and Lowe, N.J. (2001) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: ran-domised, parallel group, double blind, placebo controlled trial BMJ 323, 596–599.
14. Lowe, N.J., Lask, G., Yamauchi, P., and Moore, D. (2002) Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow’s feet J Am Acad Dermatol 47, 834–840.
15. Lowe, N.J., Ascher, B., Heckmann, M., Kumar, C., Fraczek, S., and Eadie, N. (2005) BOTOX Facial Aesthetics Study Team. Double-blind, randomized, placebo-con-trolled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet Dermatol Surg 31, 257–262.
16. Matarasso, S.L. and Matarasso, A. (2001) Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids Plast Reconstr Surg 108, 208–214.
17. Allergan, Inc. (2006) BOTOX Cosmetic (Botulinum Toxin Type A) Prescribing Information. Allergan, Inc., Irvine, CA
18. Aoki, K.R. and Guyer, B. (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions Eur J Neurol 8, 21–29.
19. Grumelli, C., Verderio, C., Pozzi, D., Rossetto, O., Montecucco, C., and Matteoli, M. (2005) Internalization and mechanism of action for clostridial toxins in neurons Neurotoxicology 26, 761–767.
20. Dutton, J.J. and Fowler, A.M. (2007) Botulinum toxin in ophthalmology Surv Ophthalmol 52, 13–31.
21. Ford, K.G., Souberbielle, B.E., Darling, D., and Farzaneh, F. (2001) Protein transduction: an alternative to genetic intervention? Gene Ther 8, 1–4.
22. Aoki, K.R. (2001) A comparison of the safety margins of botulinum toxin serotypes A, B, and F in mice Toxicon 39, 1815–1820.
23. Glogau, R.G. (2007) Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study Dermatol Surg 33, S76–S80.